Business Context and Reporting Period
Jasper Therapeutics, Inc. filed this Form 8-K on March 11, 2022, reporting events occurring on March 7, 2022, under Item 5.02. The filing concerns a leadership transition and service agreement with William Lis.
Key Financial and Operating Information
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating-performance metrics.
- Mr. Lis’s employment will terminate effective March 15, 2022.
- Mr. Lis will remain a Class III director and become non-employee Chairperson of the Board.
- The initial Chairperson term is 12 months, subject to mutual extension.
- Chairperson compensation is an annual fee of $250,000, paid in equal monthly installments.
- After board service ends, Mr. Lis will provide consulting services through the later of 12 months after the final board service date or March 15, 2024, for a monthly fee of $12,250.
- Subject to board or Compensation Committee approval, Mr. Lis will receive an option to purchase 100,000 shares of common stock, vesting in 12 substantially equal monthly installments beginning March 15, 2022.
Material Changes Versus the Prior Period
The filing reports a change in executive responsibilities: Ronald Martell was appointed President and Chief Executive Officer, while William Lis transitioned from employee to non-employee Board Chairperson and later consultant. Mr. Lis will no longer participate in the Employee Severance Plan for Vice Presidents and Executive Committee Members, and his September 24, 2021 employment agreement will terminate effective March 15, 2022.
Guidance, Outlook, Risks, and Unusual Items
- No financial guidance or business outlook is provided.
- If Mr. Lis’s service is terminated by the Company without “Cause,” he is entitled to installments of the Annual Fee through the applicable term, reduced by Monthly Fees payable for the relevant months, and the option will vest in full.
- Mr. Lis’s outstanding equity awards will continue to vest under their existing agreements.
- The new option is subject to approval by the Board or Compensation Committee and is expected to be granted after the Company files a Form S-8 registration statement.
- The Annual Fee and option replace compensation that might otherwise have been payable under the Company’s non-employee director compensation policy, unless otherwise determined by the Board or Compensation Committee.
Investor Verification Items
- Confirm Ronald Martell’s appointment and the effective date of the CEO transition.
- Review Exhibit 10.1 for the complete terms, termination provisions, definitions of “Cause,” and consulting obligations.
- Verify board or Compensation Committee approval and subsequent issuance terms for the 100,000-share option.
- Monitor the Company’s Form S-8 filing and related equity dilution disclosures.
- Assess the accounting and cash-cost impact of the $250,000 annual fee, $12,250 monthly consulting fee, and potential accelerated option vesting.